{"entity":{"id":"camel","kind":"trial","name":"CameL","aka":[],"tldr":"The trial that made camrelizumab a first-line lung cancer option in China, one of several domestic PD-1 antibodies to reproduce the KEYNOTE-189 result.","summary":"412 patients, open label. Median progression-free survival 11.3 versus 8.3 months (hazard ratio 0.60); overall survival favoured camrelizumab in later follow-up. NMPA approval June 2020. Its companion CameL-sq did the same in squamous disease. Camrelizumab is notable for reactive cutaneous capillary endothelial proliferation, a side effect largely unique to it.","status":"positive","asOf":"2026-09-10","links":[{"label":"ClinicalTrials.gov NCT03134872","url":"https://clinicaltrials.gov/study/NCT03134872"},{"label":"Lancet Respir Med 2021","url":"https://doi.org/10.1016/S2213-2600(20)30365-9"}],"tags":["china"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["camrelizumab","carboplatin","pemetrexed"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["zhou-caicun"],"bottlenecks":[],"keyPapers":["paper-camel-lancet-respir-med-2021","paper-camel-j-thorac-oncol-2023-update"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03134872","phase":"3","setting":"First-line non-squamous NSCLC without EGFR or ALK alterations, China: camrelizumab plus carboplatin and pemetrexed vs chemotherapy alone","sponsor":"Jiangsu Hengrui Pharmaceuticals","result":"PFS 11.3 vs 8.3 months, HR 0.60.","started":"2017-05-12","startedType":"actual","yearReported":2021,"enrolled":419,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Camrelizumab + chemotherapy","n":205,"value":11.3},{"name":"Chemotherapy","n":207,"value":8.3}],"hr":0.6,"source":"https://doi.org/10.1016/S2213-2600(20)30365-9"}]},"route":"/trials/camel/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"person":[{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/"}],"paper":[{"id":"paper-camel-j-thorac-oncol-2023-update","kind":"paper","name":"Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial","route":"/key-papers/paper-camel-j-thorac-oncol-2023-update/"},{"id":"paper-camel-lancet-respir-med-2021","kind":"paper","name":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-camel-lancet-respir-med-2021/"}]}}